![]() |
市场调查报告书
商品编码
1540824
2024-2032 年按技术(合成定序、连接定序、焦磷酸定序、桑格定序等)、研究类型、实验室类型、应用、最终用户和地区分類的微生物组定序服务市场报告Microbiome Sequencing Services Market Report by Technology (Sequencing by Synthesis, Sequencing by Ligation, Pyrosequencing, Sanger Sequencing, and Others), Research Type, Laboratory Type, Application, End User, and Region 2024-2032 |
IMARC Group年,全球微生物组定序服务市场规模达22.193亿美元。大众传染病发病率的增加、对包括 FMT 在内的基于微生物组的治疗的兴趣不断增加,以及微生物组测序在兽医医学中的日益采用是推动市场的一些主要因素。
微生物组定序服务涉及对居住在包括人体在内的各种环境中的微生物群落进行分析。它们是专门的程序,旨在识别和分析生活在特定生态系统(例如人类肠道、土壤或水)中的多种微生物。他们使用先进的脱氧核糖核酸 (DNA) 定序技术来解码微生物的遗传物质,使研究人员和医疗保健专业人员能够了解这些微生物群落的组成、多样性和功能。
大众传染病发病率的不断上升,促进了对用于研究宿主与病原体关係的微生物组测序服务的需求,从而导致世界各地对其服务的需求不断增加。此外,人们越来越倾向于基于微生物组的治疗,包括粪便微生物群移植(FMT),这需要准确的微生物组分析以确保治疗效果和安全性,这有利于市场的成长。除此之外,兽医学中越来越多地采用微生物组定序来了解动物健康、疾病预防和改善畜牧生产,这对市场产生了积极影响。此外,製药业的扩张正在推动利用微生物组资料来开发新药,特别是针对胃肠道疾病的新药,这有助于市场成长。此外,越来越多地采用依赖数据驱动决策的精准农业实践,正在推动市场成长。
个人化医疗和疗法的增加
随着个人化医疗的日益普及,对微生物组定序服务的需求不断增加,以便为个别患者提供量身定制的治疗和介入措施。对微生物组测序服务需求背后的驱动力之一是认识到一个人的每个微生物组都是独特的,并且可以显着影响他们对治疗的反应。无论是优化益生菌方案、指导饮食建议,或是预测药物疗效,微生物组资料都是不可或缺的。患者和医疗保健提供者越来越多地寻求这些见解,以实现更好的治疗结果、最大限度地减少不良反应并增强整体健康。因此,随着个人化医疗成为现代医疗保健的核心原则,对微生物组定序服务的需求不断增长。
消费者意识和健康的提高
消费者对微生物组在健康和保健中的作用的认识一直在稳步提高。人们对自己的健康变得更加积极主动,寻求优化微生物组以改善福祉的方法。这一趋势是由直接面向消费者的微生物组测试套件的可用性推动的,该套件为个人提供了对其肠道微生物群的深入了解。随着消费者更了解微生物组与各个健康面向之间的联繫,他们开始转向微生物组定序服务来进行深入分析和个人化建议。公众兴趣的激增正在推动对微生物组测序服务的需求,因为个人寻求做出明智的生活方式选择和饮食调整以促进更健康的微生物组。
不断增长的监管要求和品质保证
医疗保健、农业和食品安全领域的监管机构越来越认识到微生物组资料在确保安全和品质标准方面的重要性。例如,在食品工业中,微生物组定序用于透过识别潜在的病原体或腐败生物来监测和改善食品安全。同样,农业监管机构可能要求进行微生物组评估,以确保可持续的农业实践。遵守这些法规需要利用微生物组定序服务来维持高品质标准,从而导致企业和组织不断要求努力满足法规要求并确保其产品的安全性。
The global microbiome sequencing services market size reached US$ 2,219.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 9,979.3 Million by 2032, exhibiting a growth rate (CAGR) of 17.6% during 2024-2032. The increasing incidences of infectious diseases among the masses, rising inclination towards microbiome-based therapeutics, including FMT, and the growing adoption of microbiome sequencing in veterinary medicine are some of the major factors propelling the market.
Microbiome sequencing services involve the analysis of microbial communities that inhabit various environments, including the human body. They are specialized procedures designed to identify and analyze the diverse microorganisms living in a particular ecosystem, such as the human gut, soil, or water. They use advanced deoxyribonucleic acid (DNA) sequencing technologies to decode the genetic material of microorganisms, which allows researchers and healthcare professionals to understand the composition, diversity, and function of these microbial communities.
Increasing incidences of infectious diseases among the masses are catalyzing the demand for microbiome sequencing services for studying host-pathogen relationships, which lead to rising demand for its services around the world. Moreover, the rising inclination towards microbiome-based therapeutics, including fecal microbiota transplantation (FMT), that necessitates accurate microbiome profiling to ensure treatment efficacy and safety is favoring the growth of the market. Apart from this, the growing adoption of microbiome sequencing in veterinary medicine for understanding animal health, disease prevention, and improving livestock production is influencing the market positively. In addition, the expansion of the pharmaceutical industry is driving the use of microbiome data to develop novel drugs, particularly those targeting gastrointestinal diseases, which is contributing to the market growth. Furthermore, the increasing adoption of precision agriculture practices, which rely on data-driven decision-making, is bolstering the market growth.
Increase in personalized medicine and therapies
With the rising use of personalized medicine, there is a rise in the demand for microbiome sequencing services to offer tailoring treatments and interventions to individual patients. One of the driving forces behind the demand for microbiome sequencing services is the recognition that each microbiome of a person is unique and can significantly impact their response to treatments. Whether it is optimizing probiotic regimens, guiding dietary recommendations, or predicting drug efficacy, microbiome data is indispensable. Patients and healthcare providers increasingly seek these insights to achieve better treatment outcomes, minimize adverse effects, and enhance overall wellness. Consequently, the demand for microbiome sequencing services is rising as personalized medicine is becoming a central tenet of modern healthcare.
Rise in consumer awareness and wellness
Consumer awareness about the role of microbiomes in health and wellness has been steadily increasing. People are becoming more proactive about their health, seeking ways to optimize their microbiomes for improved well-being. This trend is driven by the availability of direct-to-consumer microbiome testing kits that provide individuals with insights into their gut microbiota. As consumers gain a better understanding of the connections between their microbiome and various health aspects, they are turning to microbiome sequencing services for in-depth analysis and personalized recommendations. This surge in interest from the public is propelling the demand for microbiome sequencing services, as individuals seek to make informed lifestyle choices and dietary adjustments to promote a healthier microbiome.
Growing regulatory requirements and quality assurance
Regulatory bodies in healthcare, agriculture, and food safety are increasingly recognizing the importance of microbiome data in ensuring safety and quality standards. For instance, in the food industry, microbiome sequencing is used to monitor and improve food safety by identifying potential pathogens or spoilage organisms. Similarly, regulatory agencies in agriculture may require microbiome assessments to ensure sustainable farming practices. Compliance with these regulations necessitates the utilization of microbiome sequencing services to maintain high-quality standards, leading to a consistent demand from businesses and organizations striving to meet regulatory requirements and ensure the safety of their products.
IMARC Group provides an analysis of the key trends in each segment of the market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on technology, research type, laboratory type, application, and end user.
Sequencing by Synthesis (SBS)
Sequencing by Ligation (SBL)
Pyrosequencing
Sanger Sequencing
Others
Sequencing by synthesis (SBS) dominates the market
The report has provided a detailed breakup and analysis of the market based on the technology. This includes sequencing by synthesis (SBS), sequencing by ligation (SBL), pyrosequencing, sanger sequencing, and others. According to the report, sequencing by synthesis (SBS) represented the largest segment. SBS is the fundamental technology behind microbiome sequencing services. It is employed to unravel the genetic makeup of microorganisms in a given sample. During SBS, DNA strands from the microbial community are broken down into their individual components and then precisely reconstructed. This process relies on the incorporation of fluorescently labeled nucleotides into the growing DNA strands, which emit distinct signals as they are added. These signals are detected and translated into the genetic sequence, which enables scientists to identify the types and quantities of microorganisms present in the sample. SBS is highly accurate and efficient, which makes it a cornerstone of microbiome analysis, with applications ranging from human health research to environmental monitoring.
Outsourced Research
Internal Research
Outsourced research holds the largest share in the market
A detailed breakup and analysis of the market based on the research type has also been provided in the report. This includes outsourced research and internal research. According to the report, outsourced research accounted for the largest market share. In the realm of microbiome sequencing services, research frequently encompasses an outsourced approach. This entails collaborating with external research partners or specialized service providers who possess advanced capabilities in microbiome analysis. These outsourced research endeavors are driven by the complexity and technical demands of microbiome studies. By leveraging the expertise and resources of established entities in this field, researchers can access cutting-edge sequencing technologies, bioinformatics tools, and domain-specific knowledge. This collaborative model fosters more comprehensive and insightful microbiome investigations, whether in the context of human health, environmental science, or agriculture, ultimately contributing to the advancement of knowledge in this burgeoning field.
Dry Labs
Wet Labs
Wet labs hold the largest share in the market
The report has provided a detailed breakup and analysis of the market based on the laboratory type. This includes dry labs and wet labs. According to the report, wet labs accounted for the largest market share. Wet labs are the physical spaces wherein the initial stages of microbiome sequencing occur. These labs handle the actual samples, perform DNA extraction, and prepare them for sequencing. Wet labs are equipped with state-of-the-art molecular biology instruments and techniques to ensure the integrity and quality of the genetic material from microbial communities. Scientists in wet labs use specialized protocols to isolate DNA, amplify specific regions of interest, and prepare sequencing libraries. These meticulously controlled procedures are essential to ensure accurate and reliable microbiome sequencing data. Once the sample preparation is complete, the processed samples are sent to sequencing facilities or dry labs for further analysis. Wet labs are the hands-on, experimental arm of microbiome research, where the journey from sample to data begins.
Shotgun Sequencing
Targeted Gene Sequencing
RNA Sequencing
Whole Genome Sequencing
Others
Shotgun sequencing holds the largest share in the market
A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes shotgun sequencing, targeted gene sequencing, RNA sequencing, whole genome sequencing, and others. According to the report, shotgun sequencing accounted for the largest market share. It is a powerful and comprehensive application of microbiome sequencing services. In this approach, the entire genetic material, or DNA, of a microbial community is sequenced without specifically targeting any genes or regions. This method provides a holistic view of the microbial diversity within a sample, which allows researchers to identify all the microorganisms present and gain insights into their functional potential. Shotgun sequencing is particularly useful for exploring unknown or complex microbiomes, as it does not require prior knowledge of the specific genes of interest. It is widely applied in environmental studies, such as soil and water microbiology, and has significant relevance in understanding the human gut microbiome's complexity and its implications for health. By elucidating the complete genetic makeup of microbial communities, shotgun sequencing contributes to a deeper understanding of their roles in various ecosystems and their potential applications.
Pharmaceutical and Biotechnology Companies
Research and Academic Institutes
Others
Pharmaceutical and biotechnology companies dominate the market
The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical and biotechnology companies, research and academic institutes, and others. According to the report, pharmaceutical and biotechnology companies represented the largest segment. These companies represent key end users of microbiome sequencing services. These companies leverage microbiome data to drive innovation in drug discovery, development, and therapeutic interventions. By partnering with specialized service providers, they gain access to cutting-edge sequencing technologies and expertise in microbiome analysis. This collaboration enables pharmaceutical and biotechnology companies to explore the intricate relationship between the human microbiome and health with the goal of identifying novel drug targets, biomarkers, and therapeutic candidates. Additionally, microbiome sequencing aids in the development of probiotics and microbiome-based therapies, which offer potential solutions for a range of medical conditions. As such, pharmaceutical and biotechnology firms play a pivotal role in translating microbiome research into tangible healthcare advancements, ultimately benefiting patients and advancing the field of life sciences.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest microbiome sequencing services market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
The increasing knowledge about the advantages of early diagnosis and disease detection represents one of the primary factors driving the demand for microbiome sequencing services in the North American region. Moreover, the surging prevalence of colorectal cancer (CRC) is favoring the growth of the market in the region. Besides this, the growing geriatric population, that are more prone to develop severe medical conditions, is influencing the market positively in the region.
Asia Pacific is estimated to witness stable growth, owing to increasing investment in developing novel drugs, extensive research and development (R&D) activities, integration of advanced technologies, etc.
The leading companies are adopting the use of high throughput sequencing in microbiome sequencing services to enable the simultaneous analysis of numerous microbial samples, which facilitates large-scale studies and delivers high-resolution data on microbial community composition. They are also using metagenomics that allows researchers to sequence the DNA of an entire microbial community in a sample without isolating individual species and enables a holistic view of the microbiome. Moreover, key players are integrating artificial intelligence (AI) and machine learning (ML) into microbiome data analysis that help identify patterns, predict microbial interactions, and discover biomarkers associated with health or disease, which enhances the interpretability of complex microbiome datasets.
BaseClear B.V.
Clinical-Microbiomics A/S
Diversigen Inc (OraSure Technologies Inc.)
Merieux NutriSciences
Metabiomics Corporation (BioSpherex LLC)
Microbiome Insights Inc.
Microbiome Therapeutics LLC
Molecular Research LP
Molzym GmbH & Co. KG
Resphera Biosciences LLC
Shanghai Realbio Technology (RBT) Co. Ltd.
Zymo Research Corporation
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
In 2022, Diversigen Inc (OraSure Technologies Inc.) launched metatranscriptomic sequencing and analysis services for gut microbiome samples.